ADMA

Serial Number 98538350
Registration 7686680
700

Registration Progress

Application Filed
May 7, 2024
Under Examination
Approved for Publication
Dec 24, 2024
Published for Opposition
Dec 24, 2024
Registered
Feb 11, 2025

Trademark Image

ADMA

Basic Information

Serial Number
98538350
Registration Number
7686680
Filing Date
May 7, 2024
Registration Date
February 11, 2025
Published for Opposition
December 24, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Feb 11, 2025
Registration
Registered
Classes
005

Rights Holder

ADMA BioManufacturing, LLC

16
Address
5800 Park of Commerce Blvd., NW
Boca Raton, FL 33487

Ownership History

ADMA BioManufacturing, LLC

Original Applicant
16
Boca Raton, FL

ADMA BioManufacturing, LLC

Owner at Publication
16
Boca Raton, FL

ADMA BioManufacturing, LLC

Original Registrant
16
Boca Raton, FL

Legal Representation

Attorney
David W. Staple

USPTO Deadlines

Next Deadline
2036 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2025-02-11)
Due Date
February 11, 2031
Grace Period Ends
August 11, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

9 events
Date Code Type Description Documents
Feb 11, 2025 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Feb 11, 2025 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Dec 24, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Dec 24, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Dec 18, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Nov 25, 2024 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Nov 21, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
May 7, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
May 7, 2024 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations, namely, IVIG (Intravenous Immunoglobulin); immune globulin and hyperimmune globulin for pharmaceutical purposes; immune globulin and hyperimmune globulin preparations for the treatment of primary and secondary immunodeficiencies; immune globulin and hyperimmune globulin preparations for the prevention or treatment of infectious diseases; hyperimmune globulin preparation for the prevention or treatment of hepatitis B
First Use Anywhere: Oct 10, 2019
First Use in Commerce: Oct 10, 2019

Classification

International Classes
005